Pfizer’s new crown oral medicine is effective, and the price is not cheap!

Judging from the current situation, what happened during the vaccine distribution process is likely to be repeated on the new crown oral medicine.

On Friday, local time, the global pharmaceutical leader Pfizer announced that its protease inhibitor PF-07321332 and the antiviral drug Ritonavir (collectively referred to as Paxlovid) can be used in combination to hospitalize patients with new coronary pneumonia with mild to moderate symptoms and underlying diseases in the experiment. Or the probability of death is reduced by 89%.

This is also the second drug that has been proven to significantly reduce the progression of patients with new crown infections after Merck. However, in addition to the cheers of the global capital market, how much money needs to be spent to use this new drug has become the most pressing question.

Although Pfizer did not directly announce its pricing, the company’s CEO Albert Bourla made it clear in an interview with the media on Friday that it is currently negotiating with 90 countries to supply Paxlovid. For high-income countries, the company expects the pricing to be close to Merck’s new crown oral The drug mona piravir.

According to previous disclosures by the US government, a course of Mona Piravir is 5 days, 4 capsules each in the morning and evening, and it costs US$700 in total. Bourla also said that for low-income countries, the company is also considering different options. The overall goal is to “allow these countries to have access to drugs without barriers.”

In addition to the high unit price, whether the production capacity of the new crown oral drug can meet global demand is also a problem in itself.

Although Pfizer does not expect to submit experimental data to the FDA until the end of this month, the effect that is good enough to end the trial early means that the company has great confidence in getting the EUA before the end of the year.
U.S. President Biden also made it clear on Friday that the country has secured millions of “Pfizer’s oral medicines.” This sentence also means that the 180,000 treatment courses that Pfizer is expected to produce within the year have been sold out. The company expects In 2022, the production capacity will reach 50 million treatment courses.

The British government also disclosed that it has ordered 250,000 treatment courses from Pfizer. Pfizer’s Paxlovid needs to take three tablets each morning and evening for five days.
Prior to this, the US government also spent US$1.2 billion with Merck to book 1.7 million treatment courses of Mona Piravir. The company’s current estimated production capacity is 10 million treatment courses this year + 20 million treatment courses next year.

For the majority of low- and middle-income countries, a 700-dollar course of oral medication is obviously not enough to help these countries treat the “new crown as a flu”. In addition to placing hope on the differentiated pricing of pharmaceutical companies, the United Nations-supported Pharmaceutical Patent Pool Program (MPP) has become the only hope.

On October 27th, Merck and MPP have reached an agreement to authorize other pharmaceutical companies to produce monapiravir generic drugs without patent fees and supply them to 105 low- and middle-income countries. Previously, experts estimated generic drugs. The price can be reduced to as low as 10 dollars for a course of treatment.

MPP Executive Director Charles Gore said in an interview with the media this week that many pharmaceutical companies have expressed interest in this, including pharmaceutical companies from China, India and Pakistan.

It should be noted that China is not in the 105 MPP agreement countries, which means that even if Chinese pharmaceutical companies obtain the authorization of generic drugs, drugs produced through this channel cannot be sold directly to the Chinese market.

Of course, the hope of suppressing the epidemic through oral drugs is not entirely on Pfizer and Merck. According to the previous research and development progress, Roche Pharmaceuticals’ polymerase inhibitor AT-527 and Pioneer Pharmaceutical’s AR antagonist procrulamide are also expected The results of the third phase of the experiment will be announced in the fourth quarter.


Post time: Nov-16-2021